These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24962339)

  • 1. Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway.
    Shirasaki T; Honda M; Shimakami T; Murai K; Shiomoto T; Okada H; Takabatake R; Tokumaru A; Sakai Y; Yamashita T; Lemon SM; Murakami S; Kaneko S
    Hepatology; 2014 Nov; 60(5):1519-30. PubMed ID: 24962339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.
    Honda M; Takehana K; Sakai A; Tagata Y; Shirasaki T; Nishitani S; Muramatsu T; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shimakami T; Yi M; Lemon SM; Suzuki T; Wakita T; Kaneko S;
    Gastroenterology; 2011 Jul; 141(1):128-40, 140.e1-2. PubMed ID: 21458454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C.
    Kinnman N; Andersson U; Hultcrantz R
    Scand J Gastroenterol; 2000 Dec; 35(12):1294-300. PubMed ID: 11199370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy.
    Persico M; Capasso M; Persico E; Svelto M; Russo R; Spano D; Crocè L; La Mura V; Moschella F; Masutti F; Torella R; Tiribelli C; Iolascon A
    Hepatology; 2007 Oct; 46(4):1009-15. PubMed ID: 17668875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of suppressor of cytokine signaling 3 (SOC3) by growth hormone in pro-B cells.
    Barclay JL; Anderson ST; Waters MJ; Curlewis JD
    Mol Endocrinol; 2007 Oct; 21(10):2503-15. PubMed ID: 17609438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.
    Marek B; Kajdaniuk D; Mazurek U; Janczewska-Kazek E; Kos-Kudla B; Strzalka B; Fila A; Niedziolka D; Beniowski M; Ostrowska Z; Borgiel-Marek H; Kajdaniuk J; Sieminska L; Nowak M; Wilczok T; Pakula D; Filipczyk P
    J Clin Pharm Ther; 2005 Jun; 30(3):271-7. PubMed ID: 15896245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.
    Huang Y; Feld JJ; Sapp RK; Nanda S; Lin JH; Blatt LM; Fried MW; Murthy K; Liang TJ
    Gastroenterology; 2007 Feb; 132(2):733-44. PubMed ID: 17258724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
    Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
    J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Hayashi N; Takehara T
    J Med Virol; 2014 Feb; 86(2):241-7. PubMed ID: 24338811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C.
    Guido M; De Franceschi L; Olivari N; Leandro G; Felder M; Corrocher R; Rugge M; Pasino M; Lanza C; Capelli P; Fattovich G
    Mod Pathol; 2006 Aug; 19(8):1047-54. PubMed ID: 16699498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.
    Ben-Ari Z; Pappo O; Druzd T; Sulkes J; Klein T; Samra Z; Gadba R; Tambur AR; Tur-Kaspa R; Mor E
    Cytokine; 2004 Jul; 27(1):7-14. PubMed ID: 15207246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
    Honda M; Sakai A; Yamashita T; Nakamoto Y; Mizukoshi E; Sakai Y; Yamashita T; Nakamura M; Shirasaki T; Horimoto K; Tanaka Y; Tokunaga K; Mizokami M; Kaneko S;
    Gastroenterology; 2010 Aug; 139(2):499-509. PubMed ID: 20434452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenchymal transforming growth factor beta-1: its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology.
    Calabrese F; Valente M; Giacometti C; Pettenazzo E; Benvegnu L; Alberti A; Gatta A; Pontisso P
    J Gastroenterol Hepatol; 2003 Nov; 18(11):1302-8. PubMed ID: 14535988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
    J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.